In the article, “Will the Costs of Cancer Care Ever Come Down? Speakers at AACI Meeting Discuss the Nuances of the Question,” in the November 10 issue (http://bit.ly/OT-Costs-Nov102013), information noted at the meeting about the cost for ipilimumab (Yervoy) was incorrect. As we have since been informed by a spokesperson for the drug's manufacturer, Bristol-Myers Squibb, “per the U.S. labeling, a complete course of treatment with Yervoy 3 mg/kg includes four infusions over three months and costs approximately $30,000 per infusion (this translates to a cost of approximately $120,000 for a course of therapy). The administration of Yervoy is different than most other medicines for advanced disease, which are commonly administered until progression.” We regret the error.
© 2013 by Lippincott Williams & Wilkins, Inc.